Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Prefecture Plans Venture With Firms To Support Drug Startups

This article was originally published in PharmAsia News

Executive Summary

Japan's Osaka prefecture plans to form a joint venture with private companies to support start-up firms developing biomedicines aimed at cancer and HIV/AIDS

You may also be interested in...



Coty’s Newest CEO Spent 20 Years At L’Oreal Before Founding ‘New-Age’ Skin-Care Firm Orveda

Sue Nabi’s success at L’Oreal, where she headed the firm’s global L’Oreal Paris and Lancome businesses, her skin-care savvy as founder of the luxury, “clean, green and vegan” Orveda, and her experience as a career champion of diversity were major draws for Coty, where she begins as CEO on 1 September.

Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO

Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.

Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category

A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel